Overview

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter Phase Ib study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive, follicular or marginal zone NHL who have received at least one prior rituximab-containing regimen.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Collaborators:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Rituximab